USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer
Pharmacological Research · 2025
DOI: 10.1016/j.phrs.2025.107668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2025. Verfasst von Feng Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Health Commission Key Laboratory of Birth Defect Research and Prevention & MOE Key Lab of Rare Pediatric Diseases, Department of Cell Biolog…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, B7-H1 Antigen, T-Lymphocytes, Ubiquitin-Specific Proteases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of South China, Natural Science Foundation of Guangxi Zhuang Autonomous Region, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Colorectal cancer (CRC) is characterized by a highly immunosuppressive tumor microenvironment, which limits the effectiveness of current immunotherapies. Identifying strategies to overcome this resistance is critical for improving treatment outcomes. In this study, we discovered that USP19 plays a pivotal role in regulating T-cell-mediated antitumor immunity through a CRISPR/Cas9 sgRNA library screen and co-culture assays with activated T cells. We demonstrated that USP19 deficiency significantly enhances the susceptibility to T cell-mediated cytotoxicity in CRC cells, organoids, and mouse models. Transcriptomic sequencing (RNA-seq) revealed activation of the PD-1 pathway in tumor with USP19-deficiency cells. Mechanistic investigations revealed that USP19 directly stabilizes PD-L1 by binding to its intracellular domain and preventing its degradation via K48-linked ubiquitination and proteasomal pathways. Clinically, USP19 expression was found to be significantly elevated in CRC tissues and was positively associated with PD-L1 levels, advanced tumor grade, poor differentiation, and TP53 mutations, highlighting its potential as a biomarker for aggressive CRC. Importantly, in vivo experiments demonstrated that targeting USP19, in combination with αPD-L1 therapy, synergistically suppressed CRC progression. This combination not only reduced PD-L1 levels but also enhanced CD8+ T-cell activation and GzmB infiltration, resulting in robust antitumor effects. These findings establish USP19 as a key driver of immune evasion in CRC and suggest that targeting USP19 could enhance the efficacy of immunotherapy, providing a promising new avenue for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Health Commission Key Laboratory of Birth Defect Research and Prevention & MOE Key Lab of Rare Pediatric Diseases, Department of Cell Biology and Genetics, School of Basic Medical Sciences, Hengyang Medical Sch…
- Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, Affiliated Hospital of Youjiang Medical University for Nationalities, B…
- Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, China.
- Medical Laboratory College, Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Förderung
- University of South China
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- Hunan Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Shi, F., Li, G. J., Liu, Y., Zhou, H. M., Zhang, Y., Wei, S. Y., Zan, B. J., Gao, M., Chen, F. S., Li, B. X., Wang, B. Q., Dong, M. Y., Du, R. L., & Zhang, X. D. (2025). USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer. Pharmacological Research. https://doi.org/10.1016/j.phrs.2025.107668
Vancouver
Shi F, Li GJ, Liu Y, Zhou HM, Zhang Y, Wei SY, et al. USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer. Pharmacological Research. 2025. doi:10.1016/j.phrs.2025.107668
BibTeX
@article{Shi2025,
author = {Shi, Feng and Li, Guang-Jing and Liu, Yi and Zhou, Hai-Meng and Zhang, Yue and Wei, Si-Yi and Zan, Bo-Jun and Gao, Meng and Chen, Fei-Shan and Li, Bo-Xin and Wang, Bai-Qi and Dong, Ming-You and Du, Run-Lei and Zhang, Xiao-Dong},
title = {USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer},
journal = {Pharmacological Research},
year = {2025},
doi = {10.1016/j.phrs.2025.107668}
}
EUVIMED